Gianluca Fuggetta - 23 Mar 2023 Form 4 Insider Report for Gain Therapeutics, Inc. (GANX)

Role
Principal Accounting Officer
Signature
/s/ Jason Minio, Attorney-in-Fact
Issuer symbol
GANX
Transactions as of
23 Mar 2023
Net transactions value
$0
Form type
4
Filing time
27 Mar 2023, 17:27:29 UTC
Previous filing
21 Dec 2022
Next filing
25 Mar 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GANX Employee Stock Option (right to buy) Award $0 +15,000 $0.000000 15,000 23 Mar 2023 Common Stock 15,000 $4.84 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares underlying the option shall vest 25% on March 23, 2024 and the remainder shall vest in 36 equal monthly installments thereafter, subject to Reporting Person's continuous service through each such vesting date.